BIONTECH SE SPON. ADRS 1
Commented by Mario Hose on September 1st, 2020 | 11:56 CEST
BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry
In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the potential to close a lucrative deal, because a lot is at stake for politics and economy. The necessary tests are carried out at great expense in order not to endanger human life through a vaccination, but to protect it. There are great opportunities for investors.
Read
Commented by Mario Hose on August 24th, 2020 | 06:58 CEST
BioNTech, CureVac, Valeo Pharma - the license to print money
Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because there is enormous pressure to act from all sides. The sooner vaccines or other products are available, the sooner it will be possible to return to normal everyday life. While two German pharmaceutical companies are investing a lot of money in researching a vaccine, a Canadian competitor is taking an equally exciting and less risky route.
Read
Commented by Mario Hose on August 18th, 2020 | 06:00 CEST
BioNTech, CureVac, Valeo Pharma - who is the Covid-19 winner?
The two German companies BioNTech and CureVac have already provided investors with a considerable boost in share prices. The companies have come into the public eye in recent months because they are working on a vaccine against Covid-19 and have already made great progress. Worldwide, these two companies belong to the elite in research and are a beacon of hope in the fight against the corona pandemic. While BioNTech has been listed on the stock exchange for some time, CureVac made its stock market debut last Friday - with success. Investors who have so far missed their entry in these companies should have Valeo Pharma at least on their watch list.
Read
Commented by Mario Hose on July 29th, 2020 | 07:29 CEST
BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit
The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.
Read
Commented by Mario Hose on July 15th, 2020 | 12:23 CEST
BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential
In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.
Read
Commented by Mario Hose on July 14th, 2020 | 09:17 CEST
BioNTech, Saturn Oil & Gas, TUI - Investments with potential
The stock market is diverse and investors are always looking for companies that have potential and are close to a breakthrough or can demonstrate continuity. Much has changed during the Corona Pandemic and, if you look at it closely, we are still in the middle of it. There are still some countries in the world where high rates of infection are observed. For this reason it is important that a vaccine is developed to stop the spread of COVID-19. By then at the latest, other industries will wake up from their slumber and it may therefore be worthwhile to invest in time.
Read
Commented by Mario Hose on June 18th, 2020 | 08:40 CEST
BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?
Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.
Read
Commented by Mario Hose on May 26th, 2020 | 07:43 CEST
BioNTech, Evotec, XPhyto - will the next rally start?
Germany's leading index DAX closed the previous day at 11,391 points, its highest level since March 2020. At the beginning of the week the index of the 30 largest German companies gained 317 points compared to Friday, representing a gain of 2.87%. In the USA Wall Street remained closed on Monday due to the Memorial Day. As is well known, the stock market is where the future is traded and for this reason investors are already investing in the prospects of companies in the period following the Corona Pandemic. A rally has begun.
Read
Commented by Mario Hose on May 14th, 2020 | 13:11 CEST
BioNTech, EXMceuticals, Shop Apotheke Europe, Symrise - Shares gaining momentum
The easing of measures to contain the Corona Pandemic will be further extended and, in parallel, companies and their employees will be able to increase personal communications again. However, the curfew phase was also used for strategic decisions and developments, as investors can see from announcements in recent weeks. The situation represents a crisis for many people, but it is also an opportunity for change and a new beginning. Market participants have learned in recent months that dependence on China leads to many bottlenecks and global diversification is therefore necessary. Anyone who wants to be part of it must have the right shares in their portfolio.
Read
Commented by Mario Hose on April 24th, 2020 | 07:36 CEST
BioNTech, Gilead, Memphasys - in the spotlight of investors overnight
There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.
Read